Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic blood pressure in mice. - Wikidata - awgldk - TriplyDB

Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic blood pressure in mice.

Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic blood pressure in mice.

http://www.wikidata.org/entity/Q43726340

about

Angiotensin II inhibits the Na+-K+ pump via PKC-dependent activation of NADPH oxidase DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88 12/15-lipoxygenase contributes to platelet-derived growth factor-induced activation of signal transducer and activator of transcription 3 NO-mediated regulation of NAD(P)H oxidase by laminar shear stress in human endothelial cells Cerebral Small Vessel Disease: Targeting Oxidative Stress as a Novel Therapeutic Strategy?NADPH oxidase inhibitors: a decade of discovery from Nox2ds to HTS The discovery of hypertension: evolving views on the role of the kidneys, and current hot topics NADPH oxidase in stroke and cerebrovascular disease Evolution of NADPH Oxidase Inhibitors: Selectivity and Mechanisms for Target Engagement Neuroprotection after stroke by targeting NOX4 as a source of oxidative stress Targeting NADPH oxidases in vascular pharmacology Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system Pathophysiology and Treatments of Oxidative Injury in Ischemic Stroke: Focus on the Phagocytic NADPH Oxidase 2 NADPH oxidase as a therapeutic target for oxalate induced injury in kidneys Acetylation of the pro-apoptotic factor, p53 in the hippocampus following cerebral ischemia and modulation by estrogen Localized TRPA1 channel Ca2+ signals stimulated by reactive oxygen species promote cerebral artery dilation Seizure activity results in calcium- and mitochondria-independent ROS production via NADPH and xanthine oxidase activation NADPH oxidases: key modulators in aging and age-related cardiovascular diseases?Functional heterogeneity of NADPH oxidase-mediated contractions to endothelin with vascular aging Cross talk between mitochondria and NADPH oxidases Therapeutic inhibition of mitochondrial reactive oxygen species with mito-TEMPO reduces diabetic cardiomyopathy Bridged tetrahydroisoquinolines as selective NADPH oxidase 2 (Nox2) inhibitors Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase Over-expression of calpastatin inhibits calpain activation and attenuates myocardial dysfunction during endotoxaemia Enhanced depolarization-induced pulmonary vasoconstriction following chronic hypoxia requires EGFR-dependent activation of NAD(P)H oxidase 2 Nox2 and p47(phox) modulate compensatory growth of primary collateral arteries.Hydroethidine- and MitoSOX-derived red fluorescence is not a reliable indicator of intracellular superoxide formation: another inconvenient truth Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein.X-ROS signalling is enhanced and graded by cyclic cardiomyocyte stretch.Cell-trappable fluorescent probes for endogenous hydrogen sulfide signaling and imaging H2O2-dependent H2S production.Microtubules underlie dysfunction in duchenne muscular dystrophy.Combinatorial peptide libraries: mining for cell-binding peptides.Nox2-derived reactive oxygen species mediate neurovascular dysregulation in the aging mouse brain.High oxygen tension constricts epineurial arterioles of the rat sciatic nerve via reactive oxygen species.Estrogen attenuates ischemic oxidative damage via an estrogen receptor alpha-mediated inhibition of NADPH oxidase activation Oxidative mechanisms of IL-4-induced IL-6 expression in vascular endothelium.RyR2-Mediated Ca2+ Release and Mitochondrial ROS Generation Partake in the Synaptic Dysfunction Caused by Amyloid β Peptide Oligomers.Klotho gene delivery prevents the progression of spontaneous hypertension and renal damage.NADPH oxidases in vascular pathology.The quest for selective nox inhibitors and therapeutics: challenges, triumphs and pitfalls

P2860

Q24336297-68CE40AC-3792-4A2F-9B3A-287262D7962D Q24621930-5B761C26-A22C-43A2-95C7-C48F393B714E Q24631554-581671F0-7109-40C7-A7A3-01521378841A Q24675368-6F245CDA-B24B-4F24-82C1-A026C8EE0975 Q26751153-DC7F88F9-AE92-4B34-B56A-B4505FC3BF0D Q26821775-A7CFE2FE-114C-4042-9812-A258F5388AF1 Q26830489-8028D97C-648D-41FB-9702-F36F68F491AC Q26859140-42554E70-3CDC-435E-ABF4-C0886BB9ADF2 Q26861119-B18E2010-E8AC-4051-942F-BDD5A4A13D34 Q26862779-0D2FBED6-C569-401F-B225-7E3A7925A982 Q26863500-F41F0088-F254-4310-84CD-B7C72DADD577 Q26991619-5A130015-FE5D-40BD-9F42-AA892B463E87 Q27005956-E37CC175-1603-42A1-9EDA-8B1665619FBB Q27014373-2F905032-054F-44D4-A9D1-A6F49EFA3813 Q27314528-164EF233-D8A7-47C2-BD20-D594855AC36C Q27329830-EE94BDF1-CD70-4DED-B7C7-9F5434AAE509 Q27331435-E5C0ED0D-0865-4F84-99BA-A80866D0749A Q28072348-731F44E2-459F-4DDC-B982-8F17EA2F92E6 Q28388900-456121EC-008D-4F46-A430-75E39EC85E30 Q28391403-1172BFCC-C7D4-4732-8FDE-304EE0D083ED Q28391746-7C09BFA4-9887-4443-BC3A-90AF12FB0CB5 Q28394560-A9A2700B-B4E3-4D26-B05A-E1233D08B543 Q28564620-6BAF3F3A-9D48-4308-B9EE-2DBA744B7936 Q28570460-90C040D0-3445-4176-AABA-C180F693C1D3 Q28582157-40B8A481-282F-4F67-BA38-C63D8F441E50 Q29346981-5D52F2F4-D137-4462-9F93-08D22F87E7AC Q30457642-E64C48B1-D256-4335-885A-DBE0700665D9 Q30481236-BAB7BB1A-2E6B-45C3-BBB6-FADBB597767F Q30539103-DDC9C852-B4C3-4ABD-BB45-CF94A4DA61C8 Q30539574-65F6A7EF-E254-4BD8-A890-F8DE88717490 Q30557507-F7A1D1BB-502D-4AAE-B5F0-6D8DE7433322 Q31144876-E58B3DAD-BEB2-491F-933A-367E33D7ED7B Q33281864-223122D9-5FDF-407C-9E5C-D326310C20ED Q33285130-82E3B0FA-EB3C-472A-B6AF-3D6695BAE875 Q33595388-BD4FC934-FB90-4AD1-A666-EB6A71F24F30 Q33598669-56321F8B-DEC0-438B-9343-E7A0DE85E9EF Q33600132-3CCF61B8-EAB2-4908-A26F-F93A83CD671D Q33621916-BD0A2FD9-108D-405B-A141-3A12E51B001A Q33632089-687C113E-41AA-4103-BD26-07871A493134 Q33632757-254E5CD3-8AEA-4338-B2CC-3150CB3A837E

P2860

Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic blood pressure in mice.

http://www.wikidata.org/entity/Q43726340

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

2001年學術文章

@zh

2001年學術文章

@zh-hant

name

Novel competitive inhibitor of NAD

@nl

Novel competitive inhibitor of ...... stolic blood pressure in mice.

@en

type

label

Novel competitive inhibitor of NAD

@nl

Novel competitive inhibitor of ...... stolic blood pressure in mice.

@en

prefLabel

Novel competitive inhibitor of NAD

@nl

Novel competitive inhibitor of ...... stolic blood pressure in mice.

@en

P1433

Q43726340-3986BD18-73BA-48DA-8FDC-DBB561A9509C

P1476

Q43726340-A88F4547-2141-4BF5-947C-0068308976A8

P2093

Q43726340-0772BD9E-0FD9-4874-ADD4-D17D14F53F7B

Q43726340-2FE5C1E6-496F-449F-998C-2107818083F6

Q43726340-78EE5316-4040-4179-A08E-D52AA03C27F5

Q43726340-9613DBF3-425D-4C35-BFBF-80EC68701B62

P304

Q43726340-CED3E67A-6414-44A9-84E5-669E80B86058

P31

Q43726340-B492ECB6-D232-404C-AEF4-337A3AA0638F

P356

Q43726340-2A2D99F1-15C1-4AA5-80E0-7ED779FEC390

P433

Q43726340-2468C78B-CE0F-4E5B-88CB-AB24786594F8

P478

Q43726340-9BF99643-C909-49D1-A4AD-922A6D6252D4

P50

Q43726340-76B75903-B144-4513-A108-B15F84D73B7D

P577

Q43726340-E40D6930-C479-47D7-956F-72D263529318

P5875

Q43726340-A1CCF55E-EDCF-4FF2-9465-4D020203070F

P698

Q43726340-77D3D2AD-D9B7-4514-B8B8-442B8550BE0E

P921

Q43726340-7F376B31-55AD-4B28-94F4-B944DA7895A9

P356

P1433

Circulation Research

P1476

Novel competitive inhibitor of ...... ystolic blood pressure in mice

@en

P2093

A Kiarash

http://www.w3.org/2001/XMLSchema#string

F E Rey

http://www.w3.org/2001/XMLSchema#string

M T Quinn

http://www.w3.org/2001/XMLSchema#string

P J Pagano

http://www.w3.org/2001/XMLSchema#string

P304

408-414

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/HH1701.096037

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

89

http://www.w3.org/2001/XMLSchema#string

P50

Eugenia Cifuentes-Pagano

P577

2001-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11813160

http://www.w3.org/2001/XMLSchema#string

P698

11532901

http://www.w3.org/2001/XMLSchema#string

P921